1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc.

DRUG.CN
Bright Minds Biosciences Inc.CA flagCanadian Securities Exchange
106.00
CAD
-0.82
- -
822.72MMarket Cap
Bright Minds Biosciences Inc.
DRUG.CN
(Canadian Securities Exchange)

Recent

price

106.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.38
-4.82
-6.06
-1.98
-0.65
-1.78
-3.36
Basic EPS, GAAP
-0.23
-4.08
-5.5
-1.89
-0.43
-1.26
-2.44
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.33
9.96
3.26
0.64
0.25
11.15
36.98
Book Value per Share
0.57
10.81
4.27
1.77
1.28
11.93
37.88
Tangible Book Value per Share
1
2
2
4
4
7
8
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-9
-15
-7
-3
-12
-27
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
1
19
10
7
5
82
308
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
1
19
11
7
6
82
309
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-94.59
-115.41
-141.36
-162.82
-31.46
-15.46
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
10
Market Capitalization
571
806
826

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'26
Mar'26
Total Current Assets
84
91
312
Cash, Cash Equivalents & STI
83
89
310
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
4
Payables & Accruals
2
1
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
768.63%
1,381.93%
Free Cash Flow
- -
554.28%
369.77%
Net Income, GAAP
- -
399.51%
336.46%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.44
-0.13
0.05
- -
-0.65
2025
0.01
-0.42
-0.74
- -
-1.78
2026
-0.97
-1.09
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Evogene Ltd. (EVGN.TA)
Viridian Therapeutics, Inc. (0K1R.L)
AnaptysBio, Inc. Common Stock When Issued (ANABV)
OSR Holdings, Inc. (OSRH)
Advagene Biopharma Co., Ltd. (6709.TWO)
Nkarta, Inc. (NKTX)
Business
Bright Minds Biosciences Inc. is a biotechnology firm dedicated to creating innovative treatments for patients facing severe and debilitating neurological and neuropsychiatric conditions. The company's pipeline emphasizes highly selective serotonergic agonists, precisely engineered to target 5-HT2C, 5-HT2A, and combined 5-HT2C/A receptors. Its lead compound, BMB-101, has advanced to Phase 2 clinical trials for developmental and epileptic encephalopathies and absence epilepsy, and is also being evaluated for Prader-Willi Syndrome. Additionally, BMB-201 is in preclinical development for pain and depression, having demonstrated efficacy comparable to morphine in early models, while BMB-202 is undergoing preclinical assessment for rapid-onset depression. The company engages in strategic collaborations with entities such as the National Institutes of Health for epilepsy and pain management programs, and the University of Texas Medical Branch for impulse control disorders including binge eating. Founded in 2019, Bright Minds Biosciences is headquartered in New York, NY.

Company News

APIChat

  • proactiveinvestors.com

    Bright Mind Biosciences shares surge on positive epilepsy drug trial results